Early access to Santhera’s DMD therapy Raxone extended in the UK

Early access to Santhera’s DMD therapy Raxone extended in the UK

Source: 
Pharma Times
snippet: 

UK regulators have renewed the scientific opinion for Santhera’s Raxone, extending its availability to patients with Duchenne muscular dystrophy (DMD) through the Early Access to Medicines Scheme (EAMS) for another year.